logo
Plus   Neg
Share
Email

Merck: CHMP Supports KEYTRUDA Plus Inlyta To Treat Advanced Renal Cell Carcinoma

Merck (MRK) said CHMP, the Committee of the European Medicines Agency, has recommended approval of KEYTRUDA plus Inlyta combination for the first-line treatment of patients with advanced renal cell carcinoma. The final decision by the European Commission is anticipated in the third quarter of 2019.

The CHMP recommendation is based on the results from the Phase 3 KEYNOTE-426 trial, which showed significant improvements in overall survival, progression-free survival and objective response rate for KEYTRUDA in combination with axitinib compared to sunitinib.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
The media mogul and Billionaire Sumner Redstone passed away on Tuesday at the age of 97, his family's holding company National Amusements said in a statement on Wednesday. He was Chairman Emeritus of ViacomCBS and chief executive officer of National Amusements. Customers in the U.S. are preferring digital or touchless payment methods due to concerns arising from the COVID-19 pandemic, a survey said. According to the survey by Rapyd Financial Network, the coronavirus pandemic has raised health and safety concerns around using cash and coins, and is accelerating the pre-existing trend toward digital transactions. American Airlines has extended its offer to waive change fees for customers who purchase tickets for travel, until December 31, 2020 in response to lower travel demand due to the coronavirus pandemic. This means that the travelers need not pay penalties for changing the origin and destination cities.
Follow RTT